A recent study found that use of optimal guideline-directed medical therapies after heart failure with reduced ejection fraction (HFrEF) diagnosis is low overall, but especially among female patients ...

Please provide your email address to receive an email when new articles are posted on . The American College of Cardiology and HealthReveal, an artificial intelligence company, announced a ...

prescription medicine Despite substantial advances in therapeutic options for HFrEF, significant gaps remain in the use of guideline-directed medical therapy in these patients. Heart failure affects ...

After the sponsor halted the trial, despite the DSMB’s advice to continue, investigators aimed to salvage the scientific value.

Patients with heart failure frequently suffer from fluid overload, and for those with heart failure with reduced ejection fraction (HFrEF) also suffering from septic shock—a condition often treated ...

Please provide your email address to receive an email when new articles are posted on . An analysis of the VICTORIA trial showed that the benefits of vericiguat in HF with reduced ejection fraction ...

The ACC recently issued an expert consensus decision pathway for treatment of HFrEF for 2024. The American College of Cardiology (ACC) released an expert consensus decision pathway in the Journal of ...

Vericiguat (Merck/Bayer), among the latest drugs to gain cred in heart failure (HF) with reduced ejection fraction (HFrEF), significantly benefits patients who are highly adherent to standard-of-care ...

Contemporary guidelines highly recommend patients with heart failure with reduced ejection fraction (HFrEF) be on all four drug classes that together have shown clinical clout, including improved ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Patients with HF, including those with concomitant COPD, benefit from treatment with BBs, and these drugs should be used to improve outcomes in these patients. However, not only are BBs not prescribed ...

prescription medicine Despite substantial advances in therapeutic options for HFrEF, significant gaps remain in the use of guideline-directed medical therapy in these patients. Heart failure affects ...